Anemia as a risk factor and therapeutic target in heart failure
Anemia as a risk factor and therapeutic target in heart failure
复制标题
DOI：
10.1016/j.jacc.2004.05.070
复制
发表时间：
2004-09-01
影响因子：
24
通讯作者：
O'Connor, CM
中科院分区：
文献类型：
--
作者：
Felker, GM;Adams, KF;O'Connor, CM
贫血最近被认为是心力衰竭（HF）患者的一种重要合并症和潜在的新治疗靶点。贫血在心力衰竭患者中很常见，患病率在 4% 到 55% 之间，具体取决于研究人群。贫血与心衰临床综合征之间存在多种潜在的相互作用机制，包括血液稀释、炎症激活、肾功能不全和营养不良。越来越多的观察数据库和临床试验文献表明，贫血是心力衰竭患者不良结局的独立危险因素。尽管初步数据表明贫血治疗可能会显着改善心力衰竭的症状，但积极治疗贫血也可能与高血压或血栓形成的风险增加有关。多项正在进行的研究为慢性心力衰竭贫血治疗的风险和益处的平衡提供了明确的数据。 (C) 2004 年由美国心脏病学会基金会资助。
Anemia has recently been recognized as an important comorbid condition and potentially novel therapeutic target in patients with heart failure (HF). Anemia is common in HF patients, with a prevalence ranging from 4% to 55% depending on the population studied. Multiple potential mechanisms of interaction exist between anemia and the clinical syndrome of HF, including hemodilution, inflammatory activation, renal insufficiency, and malnutrition. A growing body of literature from observational databases and clinical trials suggests that anemia is an independent risk factor for adverse outcomes in patients with HF. Although preliminary data suggest that treatment of anemia may result in significant symptomatic improvement in HF, aggressive treatment of anemia may also be associated with increased risk of hypertension or thrombosis. Multiple ongoing studies win provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF. (C) 2004 by the American College of Cardiology Foundation.